Physician profile
Bashar Bargoty
NPI 1780916775
$6,671.37
in general payments reported to CMS, 2019-2025
37 companies · $1,194 in 2025
The $1,194 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $855 · 2020: $731 · 2021: $406 · 2022: $1,019 · 2023: $1,180 · 2024: $1,286 · 2025: $1,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,640 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,640.33 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,363.83 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Insmed, INC. | $555.37 | 2019-2024 | Arikayce |
| Glaxosmithkline, LLC. | $552.96 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $459.36 | 2019-2025 | Ofev |
| United Therapeutics Corporation | $374.24 | 2020-2025 | Tyvaso, Tyvaso |
| Amgen INC. | $370.41 | 2022-2025 | Tezspire |
| Grifols USA, LLC | $292.53 | 2019-2025 | Prolastin-C Liquid |
| Janssen Pharmaceuticals, INC | $277.33 | 2019-2023 | Xarelto |
| Intuitive Surgical, INC. | $241.41 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $191.93 | 2024-2025 | Dupixent |
| Mylan Specialty L.P. | $187.75 | 2019-2024 | Yupelri |
| Pfizer INC. | $173.97 | 2020-2024 | |
| Genentech USA, INC. | $171.78 | 2019-2022 | |
| Abbott Laboratories | $145.99 | 2025 | 2nd Gen Centrimag Primary Console |
| Csl Behring | $120.04 | 2023-2024 | Kcentra |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galvanize Therapeutics, INC | $115.58 | 2025 | Aliya System |
| Genzyme Corporation | $114.89 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $99.47 | 2023-2024 | Uptravi, Opsumit |
| Abbvie INC. | $97.29 | 2020-2025 | Dalvance |
| Cumberland Pharmaceuticals, INC. | $94.25 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $88.02 | 2019-2021 | |
| Baxter Healthcare | $87.44 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Takeda Pharmaceuticals U.S.A., INC. | $59.98 | 2022-2023 | Glassia |
| Pulmonx Corporation | $51.76 | 2023-2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Allergan, INC. | $49.28 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $45.96 | 2023-2025 | |
| Verona Pharma, INC. | $42.22 | 2025 | Ohtuvayre |
| Ekos Corporation | $36.55 | 2019 | |
| Philips North America LLC | $35.69 | 2023-2024 | (Ak6) Vest Therapy |
| Alexion Pharmaceuticals, INC. | $35.04 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $29.55 | 2025 | Acthar |
| La Jolla Pharmaceutical Company | $24.07 | 2025 | Giapreza |
| Ani Pharmaceuticals, INC. | $21.02 | 2023 | Purified Cortrophin Gel |
| Shionogi INC | $20.32 | 2024 | Fetroja |
| Portola Pharmaceuticals, LLC | $16.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.70 | 2020 | |
| Advanced Respiratory, INC | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashar Bargoty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.